公开(公告)号：US20240335536A1

公开(公告)日：2024-10-10

申请号：US18255222

申请日：2021-12-02

申请人： Nkarta, Inc.

发明人： James Barnaby Trager ,  Ivan Chan ,  Don-Hong Wang ,  Guangnan Li ,  Alexandra Leida Liana Lazetic ,  Chao Guo

IPC分类号： A61K39/00 ,  C07K14/54 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783

CPC分类号： A61K39/4634 ,  A61K39/001112 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/4635 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2803 ,  C12N5/0636 ,  C12N5/0646 ,  A61K2239/26 ,  C12N2510/00

摘要： Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to Mexpress chimeric antigen receptors as well as genetically edited or otherwise engineered to alter the effectiveness with which another immune cell can target and induce cytotoxic effects on the engineered cells. In several embodiments, the methods and compositions disclosed herein reduce fratricide within a therapeutic cell population, which in some instances comprises mixture of immune cell types. Additionally, the methods and compositions disclosed herein enhance one or more aspects of the efficacy of the immune cells in cellular immunotherapy including cytotoxicity and/or persistence, as well as reduced graft versus host or host versus graft effects.

公开(公告)号：US12092635B2

公开(公告)日：2024-09-17

申请号：US18386066

申请日：2023-11-01

申请人： 10X GENOMICS, INC.

发明人： Tarjei Sigurd Mikkelsen ,  Eswar Prasad Ramachandran Iyer ,  Andrew Kohlway ,  Luigi Jhon Alvarado Martinez ,  Katherine Pfeiffer ,  Andrew D. Price

IPC分类号： G01N33/532 ,  C07K14/74 ,  C12N15/10 ,  C12N15/11 ,  C12N15/85 ,  C12Q1/6804 ,  C12Q1/6806 ,  C12Q1/6818 ,  C12Q1/6827 ,  C12Q1/6881 ,  C40B30/04 ,  C40B50/06 ,  C40B70/00 ,  G01N33/50 ,  G01N33/53 ,  G01N33/543 ,  G01N33/548 ,  G01N33/569 ,  G01N33/58

CPC分类号： G01N33/532 ,  C07K14/70539 ,  C12N15/1037 ,  C12N15/1055 ,  C12N15/1065 ,  C12N15/1075 ,  C12N15/11 ,  C12N15/85 ,  C12Q1/6804 ,  C12Q1/6806 ,  C12Q1/6818 ,  C12Q1/6827 ,  C12Q1/6881 ,  G01N33/5032 ,  G01N33/505 ,  G01N33/5304 ,  G01N33/5306 ,  G01N33/5308 ,  G01N33/54306 ,  G01N33/54366 ,  G01N33/548 ,  G01N33/56977 ,  G01N33/58 ,  C12N2310/20 ,  C12N2320/10 ,  C12Q2537/164 ,  C12Q2563/179 ,  C12Q2563/185 ,  C12Q2565/1015 ,  C40B30/04 ,  C40B50/06 ,  C40B70/00

摘要： The present disclosure provides methods of processing or analyzing a sample. A method for processing a sample may comprise hybridizing a probe molecule to a target region of a nucleic acid molecule (e.g., a ribonucleic acid (RNA) molecule), barcoding the probe-nucleic acid molecule complex, and performing extension, denaturation, and amplification processes. A method for processing a sample may comprise hybridizing first and second probes to adjacent or non-adjacent target regions of a nucleic acid molecule (e.g., an RNA molecule), linking the first and second probes to provide a probe-linked nucleic acid molecule, and barcoding the probe-linked nucleic acid molecule. One or more processes of the methods described herein may be performed within a partition, such as a droplet or well. One or more processes of the methods described herein may be performed on a cell, such as a permeabilized cell.

公开(公告)号：US20240299515A1

公开(公告)日：2024-09-12

申请号：US18673179

申请日：2024-05-23

申请人： Cue Biopharma, Inc.

发明人： Ronald D. Seidel, III ,  Rodolfo J. Chaparro ,  John F. Ross ,  Chee Meng Low

IPC分类号： A61K39/00 ,  A61P3/10 ,  A61P37/06 ,  C07K7/08 ,  C07K14/495 ,  C07K14/525 ,  C07K14/55 ,  C07K14/62 ,  C07K14/705 ,  C07K14/74 ,  C12N9/88

CPC分类号： A61K39/0008 ,  A61P3/10 ,  A61P37/06 ,  C07K7/08 ,  C07K14/495 ,  C07K14/525 ,  C07K14/55 ,  C07K14/62 ,  C07K14/70532 ,  C07K14/70539 ,  C12N9/88 ,  C12Y401/01015 ,  A61K2039/577 ,  A61K2039/605 ,  A61K2039/645 ,  C07K2319/30

摘要： The present disclosure provides T-cell modulatory multimeric polypeptides (TMMPs) comprising a type 1 diabetes (T1D)-associated peptide epitope, MHC class II polypeptides, and one or more immunomodulatory polypeptides. A TMMP of the present disclosure is useful for modulating activity of a T cell. Thus, the present disclosure provides compositions and methods for modulating the activity of T cells, as well as compositions and methods for treating persons who have T1D.

公开(公告)号：US12076346B2

公开(公告)日：2024-09-03

申请号：US18166503

申请日：2023-02-09

申请人： APPLIED STEMCELL, INC.

发明人： Ruby Yanru Tsai ,  Alfonso Farruggio ,  Xiuling Chi ,  Kai Wang

IPC分类号： A61K35/17 ,  C07K14/705 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0735 ,  G01N33/50

CPC分类号： A61K35/17 ,  C07K14/70539 ,  C07K14/70575 ,  C07K16/2896 ,  C12N5/0606 ,  G01N33/5014

摘要： The present disclosure provides compositions and methods for cell transplantation therapy based on forced expression of an exogenous HLA-F protein in donor cells to be transplanted into a subject. In some embodiments, the donor cells express an exogenous chimeric HLA-F protein comprising an extracellular region comprising an HLA-F alpha 1 domain, an HLA alpha 2 domain, an HLA-F alpha 3 domain, a linker and a β2m protein.

公开(公告)号：US20240271121A1

公开(公告)日：2024-08-15

申请号：US18633773

申请日：2024-04-12

申请人： ADOC SSF, LLC

发明人： Olivier Dalmas ,  Jonathan B. Johnston ,  Elizabeth Speltz

IPC分类号： C12N15/10 ,  C07K14/005 ,  C07K14/74 ,  C12N5/0783 ,  C40B30/04

CPC分类号： C12N15/1037 ,  C07K14/005 ,  C07K14/70539 ,  C12N5/0636 ,  C40B30/04 ,  C07K2319/02 ,  C12N2710/20022

摘要： Disclosed herein are antigenic peptide-MHC molecules, termed comPACT2.0 polypeptides, and methods of producing such molecules. Also disclosed herein are methods of producing libraries of comPACT2.0 polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells.

公开(公告)号：US20240271120A1

公开(公告)日：2024-08-15

申请号：US18263039

申请日：2022-01-28

申请人： Gigavax ApS

发明人： Henrik Pedersen ,  Hans-Henrik Kristensen

IPC分类号： C12N15/10 ,  C07K14/74 ,  C12N7/00

CPC分类号： C12N15/1037 ,  C07K14/70539 ,  C12N7/00 ,  C12N2795/14151

摘要： This invention describes the production and properties of a pMHC Multiplexer. The pMHC Multiplexer is a spatially limited composition of two different molecules, an encoding molecule (i.e. an RNA or DNA molecule), and an encoded peptide, where said encoded peptide is encoded by said encoding molecule. Furthermore, the peptide is complexed to a MHC complex and thus is part of a pMHC complex. A preferred embodiment of the invention describes the production and properties of an example pMHC Multiplexer that is a phage particle carrying on its surface a number of identical pMHC complexes, where the peptide of the pMHC complexes is encoded by the DNA contained within the phage particle, and where a covalent or non-covalent bond links a phage coat protein with a pMHC complex and/or a pMHC Multimer. Another preferred embodiment of the invention describes the production and properties of an example pMHC Multiplexer that is a eukaryotic cell carrying on its surface a number of identical pMHC complexes, where the peptide of the pMHC complexes is encoded by the DNA contained within the cell. Yet another preferred embodiment of the invention describes the production and properties of an example pMHC Multiplexer where the encoding molecule is a DNA or RNA, and where the binding of pMHC Multiplexer to T cell receptor (TCR) can be detected by PCR-based analysis. Yet another preferred embodiment of the invention describes the production and properties of an example pMHC Multiplexer that comprises one or more identical pMHC complexes, where the encoding molecule is directly linked to at least one peptide (p) of one of the pMHC complexes, and thus, the peptide (p) of the pMHC complex(es) is encoded by said encoding molecule directly linked to it.

公开(公告)号：US20240269179A1

公开(公告)日：2024-08-15

申请号：US18466966

申请日：2023-09-14

申请人： The Johns Hopkins University

发明人： Victor E. Velculescu ,  Valsamo Anagnostou

IPC分类号： A61K35/17 ,  A61K39/39 ,  A61P35/00 ,  C07K14/74 ,  C12Q1/68 ,  C12Q1/6869 ,  C12Q1/6881 ,  C12Q1/6886 ,  G01N33/569 ,  G01N33/574 ,  G16B30/00

CPC分类号： A61K35/17 ,  A61K39/39 ,  A61P35/00 ,  C07K14/70539 ,  C12Q1/68 ,  C12Q1/6869 ,  C12Q1/6881 ,  C12Q1/6886 ,  G01N33/56977 ,  G01N33/57484 ,  C12Q2600/106 ,  C12Q2600/156 ,  G16B30/00

摘要： Disclosed are methods of identifying target epitopes for a tumor of an individual using massively parallel sequencing and analyzing mutant epitopes. Also disclosed are methods of treating a tumor in an individual. Also disclosed are personalized, anti-tumor immunogenic preparations (e.g., personalized, anti-tumor chimeric antigen receptors (CAR) or chimeric antigen receptor T cell (CAR T cell)) customized for an individual cancer patient who initially responded to anti-tumor therapy and later became resistant to the therapy.

公开(公告)号：US12060399B2

公开(公告)日：2024-08-13

申请号：US17471754

申请日：2021-09-10

申请人： Immatics Biotechnologies GmbH

发明人： Heiko Schuster ,  Annika Sonntag ,  Daniel Johannes Kowalewski ,  Oliver Schoor ,  Jens Fritsche ,  Toni Weinschenk ,  Harpreet Singh ,  Colette Song

IPC分类号： C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  A61K38/00

CPC分类号： C07K14/4748 ,  C07K14/7051 ,  C07K14/70539 ,  A61K38/00

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240262885A1

公开(公告)日：2024-08-08

申请号：US18528645

申请日：2023-12-04

申请人： The Regents of The University of California

发明人： Nikolaos G. Sgourakis ,  Sara O'Rourke

IPC分类号： C07K14/74

CPC分类号： C07K14/70539 ,  C07K2317/51 ,  C07K2319/10 ,  C07K2319/22

摘要： Disclosed herein are novel glycosylated peptide receptive MHC-I complexes that allow for efficient production of glycosylated MHC-I multimers. Such glycosylated peptide receptive MHC-I complexes include a single-chain MHC-I construct and are produced in mammalian expression systems (e.g., CHO and HEK cells) that allow for the glycosylation of the complexes at one or more native positions. Multimers (e.g., tetramers) produced from the glycosylated peptide receptive MHC-I complexes provided herein advantageously allow for the identification of high-affinity T cell and natural killer cell receptors previously unidentified using traditional unglycosylated MHC tetramers.

公开(公告)号：US20240239869A1

公开(公告)日：2024-07-18

申请号：US18289674

申请日：2022-05-06

申请人： Institute for Systems Biology ,  California Institute of Technology

发明人： William Chour ,  James R. Heath ,  Jingyi Xie

IPC分类号： C07K14/74 ,  A61K39/00 ,  C40B40/10

CPC分类号： C07K14/70539 ,  A61K39/4611 ,  A61K39/4632 ,  C40B40/10 ,  C07K2319/01

摘要： Peptide-major histocompatibility (MHC) Class I nucleic acids and proteins are provided. Methods of their use, for example in methods of identifying antigen-specific T cells and adoptive cell therapy, are also provided.